Work

Thoracic Spinal Nerve Neuromodulation Therapy for Diabetic Gastroparesis: A Proof-of-Concept Study

Year: 2022

Type: article

Abstract: Diabetic gastroparesis (DGp) is associated with severe symptoms, impaired quality of life, and significant health care utilization.1 Treatment of DGp remains unsatisfactory. Metoclopramide is the only Food and Drug Administration–approved medication for gastroparesis. Gastric electrical stimulation is approved for compassionate use in refractory patients; however, it is invasive, lacks robust supporting evidence, does not consistently improve symptoms, and is associated with serious adverse events.

Source: Clinical Gastroenterology and Hepatology

DOI: 10.1016/j.cgh.2022.09.012

Authors: Tennekoon Karunaratne, Yun Yan, Audrey Eubanks, Brooke Inman, Satish Rao, Amol Sharma

Institution: Augusta University

Language: English

Topic: Gastrointestinal motility and disorders

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,800